Health inequalities in the burden of IBD among WCBA. حسب Jiefeng Zhao (9090305)

الموضوعات:

Frontier analysis for the potential for improvement in reducing the burden of IBD among WCBA across 204 countries and regions. حسب Jiefeng Zhao (9090305)

الموضوعات:

Decomposition analysis of the changes in prevalence (A), DALYs (B), and mortality (C) rates of IBD among women across global, 5 SDI and 21 GBD regions. حسب Jiefeng Zhao (9090305)

الموضوعات:

Estimated prevalence (A), DALYs (B), and mortality (C) rates for IBD among WCBA by 2040. حسب Jiefeng Zhao (9090305)

الموضوعات:

The global changes of AS prevalence, DALYs, and mortality rates of IBD among women from 1990 to 2021. حسب Jiefeng Zhao (9090305)

الموضوعات:

Estimated prevalence (A), DALYs (B), and mortality (C) rates of IBD in different age subgroups of WCBA by 2040. حسب Jiefeng Zhao (9090305)

الموضوعات:

The global changes of prevalence (A-C), DALYs (D-F), and mortality (G-I) rates of IBD among WCBA from 1990 to 2021. حسب Jiefeng Zhao (9090305)

الموضوعات:

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Significantly Enriched Pathways. حسب Jiyong Zhang (2498740)

الموضوعات:

Trends in the burden of stroke attributed to smoking. حسب Jaber S. Alqahtani (8822396)

Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. حسب Cathryn S. D. Maienza (20629929)

Modified version of the Caregiving Stress Model for Post Intensive Care Syndrome – Family impairments. حسب Cristobal Padilla-Fortunatti (21376807)

الموضوعات:

SPIRIT schedule: Timeline of recruitment and assessment. <i>t</i>₀: Daily screening; <i>t</i>₁: Between the 3^rd and 10^th day of ICU admi... حسب Cristobal Padilla-Fortunatti (21376807)

الموضوعات: